Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

Bibliographic Details
Main Authors:	Satzger, Imke, Marks, Lena, Kerick, Martin, Klages, Sven, Berking, Carola, Herbst, Rudolf, Völker, Bernward, Schacht, Vivien, Timmermann, Bernd, Gutzmer, Ralf
Format:	Online
Language:	English
Published:	Impact Journals LLC 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741972/

Similar Items

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
by: Wilmott, J S, et al.
Published: (2013)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten−/− melanoma
by: Scortegagna, Marzia, et al.
Published: (2013)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma
by: Sabbatino, F, et al.
Published: (2015)

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
by: Yancovitz, Molly, et al.
Published: (2012)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
by: Chen, Brenden, et al.
Published: (2012)

Biological insights into BRAFV600 mutations in melanoma patient: Not mere therapeutic targets
by: Improta, Giuseppina, et al.
Published: (2013)

Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
by: Sapkota, Bishu, et al.
Published: (2013)

Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot
by: Iwama, Eimei, et al.
Published: (2015)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA
by: Rossella Salemi, et al.
Published: (2018-08-01)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
by: Giovannoni, Sara, et al.
Published: (2015)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

Amelanotic melanoma presenting with plasmacytoid morphology and BRAF V600 mutation
by: Linda Kocovski, et al.
Published: (2015-06-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi, Maria, et al.
Published: (2016)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Zepeda-Lopez, Priscilla Denise, et al.
Published: (2016)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
by: Kocovski, Linda, et al.
Published: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
by: Yamazaki, Naoya, et al.
Published: (2015)

Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
by: Kretschmer, Lutz, et al.
Published: (2015)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
by: Fedorenko, Inna V., et al.
Published: (2015)

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
by: Gentilcore, Giusy, et al.
Published: (2013)

Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
by: Ott, Patrick A., et al.
Published: (2013)

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
by: Thomas Strub, et al.
Published: (2018-08-01)

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells
by: Loria, Rossella, et al.
Published: (2014)

NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
by: Uguen, Arnaud, et al.
Published: (2015)

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
by: Jenkins, Molly H., et al.
Published: (2015)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
by: Dorris, Emma R., et al.
Published: (2016)

Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAFV600E Melanoma
by: Wieder, Shira Y., et al.
Published: (2015)

Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis
by: Shih, Vanessa, et al.
Published: (2015)

In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma
by: Guo, Xingyi, et al.
Published: (2015)

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
by: Fofaria, Neel M., et al.
Published: (2015)

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma
by: Trudel, Stéphanie, et al.
Published: (2014)

BRAFV600E melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity
by: Whipple, C A, et al.
Published: (2014)

Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma
by: Siroy, Alan E., et al.
Published: (2014)

Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition
by: Abildgaard, Cecilie, et al.
Published: (2014)

BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
by: Kemper, Kristel, et al.
Published: (2016)

Melanoma-Derived BRAFV600E Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion
by: Kurgyis, Zsuzsanna, et al.
Published: (2016)

A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
by: Rad, Roland, et al.
Published: (2013)

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600
by: Skorokhod, Alexander, et al.
Published: (2013)

Variations of BRAF mutant allele percentage in melanomas
by: Hélias-Rodzewicz, Zofia, et al.
Published: (2015)

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
by: Penna, Ilaria, et al.
Published: (2015)